Cell and Gene Therapy Today—December 18, 2025
This week’s Cell & Gene Therapy update highlights major developments,…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Hematology Today—November 10, 2025
This week’s Hematology update spotlights  fresh breakthroughs, regulatory…
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A Professional…
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital Therapeutics
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital…
ESGCT 2025 Preview: Key Gene & Cell Therapy Highlights to Watch
ESGCT 2025 at a glance Ahead of ESGCT 2025, LucidQuest outlines the…
Cell and Gene Therapy Weekly News - September 18th 2025
Gene & Cell Therapy Update: Remedium–Lilly Obesity Pact, RMAT for…
Cell and Gene Therapy Weekly News - August 28th 2025
🧬 This Week in Gene & Cell Therapy: Rocket Pharma, RMATs, CAR-T…
Cell and Gene Therapy Weekly News - August 21st 2025
🧬 This Week in Gene & Cell Therapy: Elevidys Safety Data, CAR-T Updates,…
Cell and Gene Therapy Weekly News - August 7th 2025
🧬 This Week in Gene & Cell Therapy: Orphan Drug Win, Vision Breakthrough,…